Literature DB >> 15527706

Treatment of the antiphospholipid antibody syndrome.

Christopher Wu1, Kenneth Kalunian.   

Abstract

Numerous questions exist regarding the proper management of patients with the antiphospholipid antibody syndrome (APS). Several recent, randomized-controlled trials have been conducted that attempt to answer the fundamental questions of whom to treat, how to treat, and for how long treatment should last. These studies suggest that APS should be categorized by disease manifestations, and these presentations may have different treatment algorithms. A better understanding of the immune mechanisms that govern thrombosis in this syndrome has led to a wide array of innovative treatment approaches that will require meticulous study.

Entities:  

Mesh:

Year:  2004        PMID: 15527706     DOI: 10.1007/s11926-004-0026-z

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  35 in total

Review 1.  Prognosis in antiphospholipid syndrome.

Authors:  M C Amigo
Journal:  Rheum Dis Clin North Am       Date:  2001-08       Impact factor: 2.670

2.  Treatment of the antiphospholipid syndrome.

Authors:  Michael D Lockshin; Doruk Erkan
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

Review 3.  Safety of low-molecular-weight heparin in pregnancy: a systematic review.

Authors:  B J Sanson; A W Lensing; M H Prins; J S Ginsberg; Z S Barkagan; E Lavenne-Pardonge; B Brenner; M Dulitzky; J D Nielsen; Z Boda; S Turi; M R Mac Gillavry; K Hamulyák; I M Theunissen; B J Hunt; H R Büller
Journal:  Thromb Haemost       Date:  1999-05       Impact factor: 5.249

4.  Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.

Authors:  M H Rosove; P M Brewer
Journal:  Ann Intern Med       Date:  1992-08-15       Impact factor: 25.391

5.  Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

Authors:  R Rai; H Cohen; M Dave; L Regan
Journal:  BMJ       Date:  1997-01-25

6.  Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals.

Authors:  José A Girón-González; Enrique García del Río; Carmen Rodríguez; Javier Rodríguez-Martorell; Ascensión Serrano
Journal:  J Rheumatol       Date:  2004-08       Impact factor: 4.666

7.  TNFalpha DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome.

Authors:  M Blank; I Krause; G Wildbaum; N Karin; Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

8.  Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.

Authors:  Steven R Levine; Robin L Brey; Barbara C Tilley; J L P Thompson; Ralph L Sacco; Robert R Sciacca; A Murphy; Yimeng Lu; Teresa M Costigan; Candi Rhine; Bruce Levin; Douglas A Triplett; J P Mohr
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

9.  Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus.

Authors:  C Drenkard; A R Villa; D Alarcón-Segovia; M E Pérez-Vázquez
Journal:  J Rheumatol       Date:  1994-06       Impact factor: 4.666

Review 10.  LJP 1082: a toleragen for Hughes syndrome.

Authors:  J T Merrill
Journal:  Lupus       Date:  2004       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.